Oramed Pharmaceuticals Inc
NASDAQ:ORMP

Watchlist Manager
Oramed Pharmaceuticals Inc Logo
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
Watchlist
Price: 3.08 USD 0.33% Market Closed
Market Cap: 122.6m USD

Oramed Pharmaceuticals Inc
Investor Relations

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The firm has three product pipelines: ORMD-0801 type 2, ORMD-0801 type 1 and ORMD-0901. ORMD-0801 allows insulin to travel from the gastrointestinal tract via the portal vein to the bloodstream, where the insulin is delivered. The company is in Phase III of clinical trials. ORMD-0901 (GLP-1 capsule), aids in the balance of blood-sugar levels and decreases appetite. The firm is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary Oravax Medical Inc., or Oravax.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Nadav Kidron Esq.
President, CEO & Executive Chairman
No Bio Available
Dr. Miriam Kidron Ph.D.
Chief Scientific Officer & Director
No Bio Available
Mr. Avraham Gabay
CFO, Treasurer & Secretary
No Bio Available
Mr. Joshua Hexter
Chief Operating & Business Officer
No Bio Available

Contacts

Address
NEW YORK
New York City
1185 Avenue Of The Americas, 3Rd Floor
Contacts
+16468441164.0
www.oramed.com